Table I.
Demographic and Clinical Characteristics of the Randomized Sample at Baseline
| Measure | High Dose CrPic (n=8) |
Moderate Dose CrPic (n=9) |
Placebo (n=7) |
Test Statistica | df | pb | |||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||||
| Female | 6 | 75 | 7 | 78 | 7 | 100 | 2.00 | 2 | 0.93 |
| White | 8 | 100 | 7 | 78 | 6 | 86 | 2.96 | 4 | 0.93 |
| Mean | SD | Mean | SD | Mean | SD | ||||
| Age (years) | 41.4 | 8.5 | 35.1 | 12.4 | 37.9 | 10.8 | 1.33 | 2 | 0.93 |
| Weight (kg) | 99.9 | 21.8 | 96.3 | 26.8 | 100.0 | 16.1 | 0.53 | 2 | 0.93 |
| Body mass index (kg/m2) | 34.9 | 4.1 | 33.5 | 7.0 | 34.3 | 5.4 | 0.15 | 2 | 0.93 |
| Fasting plasma glucose (mg/dL) | 90.6 | 10.0 | 92.8 | 13.8 | 91.4 | 8.4 | 0.03 | 2 | 0.99 |
| Glycated hemoglobin (HbA1c, %) | 5.4 | 0.3 | 5.7 | 0.5 | 5.4 | 0.3 | 0.79 | 2 | 0.99 |
| QIDS-SR16 | 7.1 | 5.4 | 8.1 | 3.0 | 5.7 | 3.0 | 1.77 | 2 | 0.99 |
| Binge episodes (past 28 days) | 31.0 | 24.8 | 12.8 | 3.6 | 16.7 | 9.5 | 6.67 | 2 | 0.29 |
| EDEQ-global | 3.3 | 1.3 | 3.2 | 0.9 | 3.4 | 0.7 | 0.08 | 2 | 0.99 |
| EDEQ-eating concern | 3.0 | 1.9 | 3.0 | 1.0 | 3.2 | 1.7 | 0.03 | 2 | 0.99 |
| EDEQ-shape concern | 4.6 | 1.4 | 4.3 | 1.1 | 4.5 | 0.8 | 0.56 | 2 | 0.99 |
| EDEQ-weight concern | 4.2 | 1.5 | 3.9 | 0.9 | 4.0 | 1.3 | 1.20 | 2 | 0.99 |
| EDEQ-restraint | 1.4 (1.5) | 1.9 (1.4) | 1.8 (1.4) | 1.21 | 2 | 0.99 | |||
a
The test statistic is a Kruskal-Wallis statistic for continuous variables and a chi-square statistic (df) for categorical variables.
b
All p-values adjusted with Benjamini-Hochberg false discovery rate (FDR) procedure.